ABSTRACT: Background:Pancreatic cancer (PC) is a deadly disease with poor prognosis in the general population. We aimed to quantitate overall survival of patients with PC after irreversible electroporation (IRE) and the incidence of relevant complications. Methods:We performed a literature search via five electronic databases (PubMed, Embase, Web of Science, Scopus, and Cochrane Library databases) up to August 2017. The primary outcomes were overall survival and prognosis. Secondary outcomes included the response of post-IRE complications. Fixed-effects or random-effects meta-analysis was conducted to pool these data. Results:A total of 15 eligible articles involving 535 patients were included. The primary outcomes showed that the pooled prevalence estimates of overall survival were 94.1% (95% CI: 90.7-97.5), 80.9% (95% CI: 72.5-89.4), 54.5% (95% CI: 38.3-70.6), and 33.8% (95% CI: 14.2-53.5) at 3, 6, 12, and 24 months, and the pooled prevalence data of complete response (CR) at 2 months, partial response (PR) at 3 months, and progression at 3 months were 12.5% (95% CI: 2.9-22.2), 48.5% (95% CI: 39.4-57.6), and 19.7% (95% CI: 7.3-32.2), respectively. The secondary outcomes showed that the pooled prevalence values of post-IRE complications were abscess 6.6% (95% CI: 0.2-13), fistula 10.6% (95% CI: 2.5-18.7), pain 33.5% (95% CI: 14.5-52.5), infection 16.1% (95% CI: 3.9-28.4), thrombosis 4.9% (95% CI: 1.2-8.5), pancreatitis 7.2% (95% CI: 3.1-11.2), bleeding 4.2% (95% CI: -0.5-8.9), cholangitis 4.2% (95% CI: -0.5-8.9), nausea 9.6% (95% CI: 4.4-14.8), biliary obstruction 13.8% (95% CI: 4.2-23.3), chest tightness 7.6% (95% CI: 0.5-14.6), and hypoglycemia 5.9% (95% CI: -0.4-12.2). Conclusions:This meta-analysis indicated a clear survival benefit for PC patients who received irreversible electroporation therapy, although future safety and effectivity monitoring from more large-scale studies will be needed.
